Prof Matsabisa is currently the Director of the Indigenous Knowledge Systems (Health) Lead Programme (IKS) within the Department of Pharmacology, School of Clinical Medicine, and Faculty of Health Sciences at the University of the Free State. Prof Matsabisa is a Guest Professor at the Beijing University of Chinese Medicines (BUCM). He is the Director of the DSI-TIA-UFS IKS platform known as African Medicines Innovations and Technology Development (AMITD).
He is a current member of the Complementary Medicines Committee (CMC) of South African Health Products Regulatory Authority (SAHPRA) and a reviewer of Complimentary medicines product dossiers. He is the vice-chair of the CMC - Pharmaceutical and Analytical committee. He is currently a member and chairperson of an expert Group set up by SAHPRA to advice on the establishment of a regulatory and registration framework for African Traditional Medicines proprietary commercial products and chairs the working group. Prof Matsabisa is a member of the WHO Afro Regional Expert Committee on Traditional Medicines for COVID-19 of which he is a chairperson of. He continues to be used as a resource person for the SADC on research in traditional medicines and IKS.
He is also a member of the steering committee on access and benefit-sharing review of the Biodiversity Management Act.
Prof Matsabisa serves in the South African Bureau of Standards (SABS) traditional Medicines Standards Committee which is part of the International standards settings for herbal and traditional medicinal products. He is the deputy president of the South African Society for Basic and Clinical Pharmacology (SASBCP), and a member of the African Organization for Standardization (ARSO) on herbal medicines standards and pharmacopoeia. Prof Matsabisa is a member of Plant Based Medicines Task Force for Medical Therapies Commission of the International League Against Epilepsy (ILAE).
LinkedIn:
https://www.linkedin.com/in/motlalepula-matsabisa-226937206/